Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Globe Newswire•03/08/2026•08:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.